{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:12Z","timestamp":1786649352364,"version":"build-2736575974"},"reference-count":5,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Duloxetine is a newly introduced drug. It is being prescribed for the management of diabetic neuropathic pain and major depressive disorder. The most frequently observed adverse events with duloxetine are nausea, dry mouth and somnolence, constipation, diarrhea, decreased appetite, weight loss, feeling of fatigue, dizziness, somnolence, hypohidrosis, decreased libido and erectile dysfunction. One of the patients being prescribed the drug developed bleeding gums on being started with the drug which resolved on stopping it. We hereby report this case.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.30328","type":"journal-article","created":{"date-parts":[[2009,2,26]],"date-time":"2009-02-26T01:27:48Z","timestamp":1235611668000},"page":"44-45","source":"Crossref","is-referenced-by-count":11,"title":["Bleeding gums"],"prefix":"10.4103","volume":"53","author":[{"given":"YPS","family":"Balhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ST","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20240205","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/01443610500227961","article-title":"Neurobiology of stress urinary incontinence: New insights and implications for treatment","volume":"25","author":"Cardozo","year":"2005","journal-title":"J Obstet Gynaecol"},{"key":"R2-16-20240205","first-page":"19","article-title":"Duloxetine: A new treatment for the emotional and physical symptoms of depression","volume":"5","author":"Mallinckrodt","year":"2003","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R3-16-20240205","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1517\/14740338.4.6.987","article-title":"Safety and adverse event profile of duloxetine","volume":"4","author":"Wernicke","year":"2005","journal-title":"Exp Opin Drug Saf"},{"key":"R4-16-20240205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14740338.4.2.337","article-title":"Selective serotonin re-uptake inhibitors and the risk of bleeding","volume":"4","author":"Weinrieb","year":"2005","journal-title":"Exp Opin Drug Saf"},{"key":"R5-16-20240205","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0033-3182(99)71248-X","article-title":"Is inhibition of nitric oxide synthase a mechanism for SSRI-induced bleeding?","volume":"40","author":"Shen","year":"1999","journal-title":"Psychosomatics"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-200753010-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:54Z","timestamp":1786647174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-200753010-00016"}},"subtitle":["Duloxetine may be the cause"],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.30328","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2007]]}}}